{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:45:53Z","timestamp":1793879153036,"version":"4.7.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejca.2026.116887","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:58:24Z","timestamp":1781308704000},"page":"116887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Real-world outcomes of adjuvant therapy after curative-intent resection for biliary tract cancer"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-1228","authenticated-orcid":false,"given":"Yawen","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6700-9163","authenticated-orcid":false,"given":"David","family":"Pereyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9684-8918","authenticated-orcid":false,"given":"Vanja","family":"Podrascanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Santol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0448-0588","authenticated-orcid":false,"given":"Markus","family":"Ammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7036-3910","authenticated-orcid":false,"given":"Niall","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel A.","family":"Kankeu Fonkoua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8686-4867","authenticated-orcid":false,"given":"Rondell P.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8280-056X","authenticated-orcid":false,"given":"Caitlin B.","family":"Conboy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6104-6489","authenticated-orcid":false,"given":"Nguyen H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne G.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory L.","family":"Smoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4666-5337","authenticated-orcid":false,"given":"Patrick P.","family":"Starlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejca.2026.116887_bib1","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline","volume":"37","author":"Shroff","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116887_bib2","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001672","article-title":"Anatomic subsets of cholangiocarcinoma: more different than alike","author":"Dong","year":"2026","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ejca.2026.116887_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100378","article-title":"How I treat biliary tract cancer","volume":"7","author":"Lamarca","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116887_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.776863","article-title":"Recurrent Intrahepatic Cholangiocarcinoma - Review","volume":"11","author":"Bekki","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116887_bib5","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jamcollsurg.2015.09.005","article-title":"Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection","volume":"221","author":"Groot Koerkamp","year":"2015","journal-title":"J Am Coll Surg"},{"issue":"1","key":"10.1016\/j.ejca.2026.116887_bib6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13014-022-02091-6","article-title":"Postoperative recurrent patterns of gallbladder cancer: possible implications for adjuvant therapy","volume":"17","author":"Yuan","year":"2022","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116887_bib7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/jso.24836","article-title":"Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: a multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium","volume":"117","author":"Krasnick","year":"2018","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116887_bib8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijrobp.2008.10.052","article-title":"Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience","volume":"75","author":"Gold","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ejca.2026.116887_bib9","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ijrobp.2009.12.031","article-title":"Postoperative chemoradiotherapy for extrahepatic bile duct cancer","volume":"79","author":"Park","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ejca.2026.116887_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/COC.0b013e318209aa29","article-title":"Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience","volume":"35","author":"Kim","year":"2012","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116887_bib11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"issue":"8","key":"10.1016\/j.ejca.2026.116887_bib12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116887_bib13","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1097\/HEP.0000000000000046","article-title":"Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial","volume":"77","author":"Jeong","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejca.2026.116887_bib14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2026.116887_bib15","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116887_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116887_bib17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/oncolo\/oyad203","article-title":"Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P-Values","volume":"29","author":"Fojo","year":"2024","journal-title":"Oncologist"},{"issue":"10372","key":"10.1016\/j.ejca.2026.116887_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2026.116887_bib19","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1097\/JS9.0000000000002161","article-title":"The efficacy of adjuvant chemotherapy for curative resected biliary tract cancers: a systematic review and network meta-analysis of randomized clinical trials","volume":"111","author":"Peng","year":"2025","journal-title":"Int J Surg"},{"key":"10.1016\/j.ejca.2026.116887_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115342","article-title":"Adjuvant chemotherapy compared to observation in resected biliary tract cancers: Survival meta-analysis of phase-III randomized controlled trials","volume":"220","author":"Akkus","year":"2025","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116887_bib21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00423-023-03169-9","article-title":"Difficulty of adjuvant chemotherapy administration in patients with biliary tract cancer","volume":"408","author":"Sumiyoshi","year":"2023","journal-title":"Lange Arch Surg"},{"issue":"2","key":"10.1016\/j.ejca.2026.116887_bib22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.hpb.2019.06.019","article-title":"The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis","volume":"22","author":"Mackay","year":"2020","journal-title":"HPB (Oxf)"},{"issue":"1","key":"10.1016\/j.ejca.2026.116887_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12957-019-1732-3","article-title":"Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data","volume":"17","author":"Chikhladze","year":"2019","journal-title":"World J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116887_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12957-024-03393-7","article-title":"Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study","volume":"22","author":"Poiraud","year":"2024","journal-title":"World J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116887_bib25","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.21873\/anticanres.13329","article-title":"The Efficacy and Limitations of Postoperative Adjuvant Chemotherapy in Patients With Extrahepatic Cholangiocarcinoma","volume":"39","author":"Morino","year":"2019","journal-title":"Anticancer Res"},{"issue":"24","key":"10.1016\/j.ejca.2026.116887_bib26","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2026.116887_bib27","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2026.116887_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1365-182X(17)30755-4","article-title":"The Brisbane 2000 Terminology of Liver Anatomy and Resections","volume":"2","author":"Strasberg","year":"2000","journal-title":"HPB"},{"issue":"5","key":"10.1016\/j.ejca.2026.116887_bib29","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/SLA.0000000000006127","article-title":"An APRI+ALBI-Based Multivariable Model as a Preoperative Predictor for Posthepatectomy Liver Failure","volume":"281","author":"Santol","year":"2025","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejca.2026.116887_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zraa043","article-title":"Combined APRI\/ALBI score to predict mortality after hepatic resection","volume":"5","author":"Starlinger","year":"2021","journal-title":"BJS Open"},{"issue":"2","key":"10.1016\/j.ejca.2026.116887_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.ejca.2026.116887_bib32","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.surg.2010.10.001","article-title":"Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS)","volume":"149","author":"Rahbari","year":"2011","journal-title":"Surgery"},{"issue":"10","key":"10.1016\/j.ejca.2026.116887_bib33","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/aje\/kwi307","article-title":"Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods","volume":"162","author":"Zhou","year":"2005","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ejca.2026.116887_bib34","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12885-015-1498-0","article-title":"Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial","volume":"15","author":"Stein","year":"2015","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2026.116887_bib35","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1245\/s10434-023-13533-0","article-title":"Major Postoperative Complications Limit Adjuvant Therapy Administration in Patients Undergoing Pancreatoduodenectomy for Distal Cholangiocarcinoma or Pancreatic Ductal Adenocarcinoma","volume":"30","author":"Macfie","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2026.116887_bib36","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2026.116887_bib37","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa2405195","article-title":"Preoperative chemoradiotherapy for resectable gastric cancer","volume":"391","author":"Leong","year":"2024","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:16:12Z","timestamp":1787112972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"alternative-id":["S0959804926006684"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116887","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes of adjuvant therapy after curative-intent resection for biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116887"}}